Opdivo misses in latest GBM readout

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab plus standard of care failed to significantly improve progression-free survival (PFS) vs. SOC alone in the Phase III CheckMate -548 trial to t...